INTRODUCTION AND PURPOSE:

Roche Pharmaceuticals (Israel) Ltd. (“Roche”), part of the F. Hoffmann-La Roche group, is committed to a healthier future, continuously advancing science and ensuring everyone has access to the healthcare they need today and for generations to come. As part of this commitment, Roche is pleased to undertake and sponsor, in partnership with Sheba Medical Center (“Medical Center”) & Startup Nation Central Ltd. (CC) (“SNC”), the challenge herein with respect to breast cancer (the activity described in this document: “Challenge”).

NO PURCHASE OR PAYMENT IS REQUIRED TO ENTER OR TO WIN AND NO PURCHASE OR PAYMENT SHALL BE ACCEPTED.

CHALLENGE DESCRIPTION:

The Challenge begins on the Challenge Launch Date recorded below (“Challenge Launch”) and ends on the completion of the Pilot (as defined below) offered to the winner of the Challenge (“Winner Announcement”, and “Challenge Period“, respectively). Entry into the Challenge by any entity (“Entrant” or “Participant”) does not constitute entry into any other challenge or program, including, without limitation, other similar challenges or programs offered by Roche. By participating in the Challenge, each Entrant unconditionally accepts and agrees to comply with and abide by all the terms and provisions of this document (“Official Rules”) and the decisions of Roche regarding the Challenge, which shall be final and binding in all respects.

Main steps of the Challenge are as follow:

• Challenge Launch Date (Submission Opening): August 26, 2025
• Submission Deadline: September 25, 2025
• Finalists Notification Date: November 12, 2025
• Advisory Committee meeting with finalists: November 18, 2025
• Finalists Global Showcase Event Date and announcement of Winner: November 26, 2025
• Submission of final Pilot protocol to Medical Center independent review board (Helsinki committee), if required: by no later than 3 months of the Finalist Showcase Event Date and announcement of Winner, it being clarified that such date may be prolonged by Roche.
• Pilot completion: by no later than 9 months from the date of submission recorded above (and if no submission is required – 9 months from commencement of the Pilot).
• Transfer to Roche of final report detailing the results of the Pilot as well as all anonymized raw data obtained in the course of the Pilot: up to 60 days from completion of Pilot.
• Presentation of outcome of the Pilot at a global event: up to 12 months from complementation of the Pilot.

*All dates are subject to change at the Roche’s discretion.

ELIGIBILITY:

The Challenge is open to the following Entrants: privately held companies formed and registered under the laws of Israel with a company ID (ח.פ.), or technology transfer offices/entities of non-profit and/or governmental entities (such as universities, hospitals and health funds) (“TTO/s”), which develop a project/solution as recorded in the following paragraph. We welcome solutions with a Technology Readiness Level (TRL) of 6 and above.

The Challenge can be answered by innovative technology solutions supporting breast cancer patients in one of the following fields:

Areas of focus:

1. Adherence and Compliance

For example:

• • Patient treatment awareness and accessible information, including supporting shared decision making
  • Patient adherence to treatment regimen and workup
  • Treatment management optimization
  • Digital medication wallet
  • Management based on drug-drug interactions

2. Monitoring and Proactive Communication

For example:

• • Remote monitoring systems: symptoms, wearables, test results, etc.
  • Integrated care management systems (including documentation for both patients and medical team)
  • Patient reported outcomes (PROMs) – systematically collecting data directly from patients about their health status, including symptoms, functional abilities etc.

3. Quality of Life

For example:

• • Enhancing emotional journey and returning to daily activities
  • Improving overall quality of life during and after breast cancer treatment: insomnia, fatigue, Chemo Induced Cognitive Dysfunction (CICD), Treatment-Related Sexual Dysfunction, Lymphedema etc.

Good solutions will address at least one of these areas of focus, while great solutions will tackle more than one area of focus and support inter-connectivity standards. An advantage will be given to the first two areas of focus (i.e. Adherence and Compliance & Monitoring and Proactive Communication). Solutions should be compatible to effectively utilize the below prize offered to the winner, i.e. undertake a Pilot at the Medical Center as outlined below. Finally, technologies that are in the process of obtaining regulatory approval, have already received it, or are currently deployed in the market – an advantage.

Finalists must commit to making themselves available for an in-person meeting at SNC with the Advisory Committee as well as for the Finalists Global Showcase Event.

HOW TO ENTER:

To enter the Challenge, go to the website located at https://better-future.co.il, follow the link to the Official Entry Form located at the SNC website (“Submission Website“), and submit your submission according to the instructions posted on said websites and the Official Rules (collectively: “Submission Requirements” and the submission of each Entrant: “Submission”). Any Submission that violates the Submission Requirements may be disqualified by Roche. By placing a Submission, Entrant affirms that it has read and agreed to all the terms and provisions of these Official Rules. It is recorded that the Submission Website is a website of SNC with which Roche collaborates in various aspects of the Challenge.

Submissions must be received during the period commencing of the Challenge Launch Date recorded above and ending on September 25, 2025 (“Submission Period”). Roche is the official timekeeper for the Challenge. Unless approved otherwise by Roche on a case-by-case basis, no substitutions or new versions of Submissions will be accepted under any circumstances once the original Submission is submitted for consideration. Personal information collected in connection with the Challenge (including any personal information contained in a Submission) will be used by Roche in accordance with Roche’s privacy policy located at https://better-future.co.il/privacy-statement-2025/ and such information, including without limitation name, mailing address, phone number, and email address may be collected, processed, stored and otherwise used by Roche inter alia for the purposes of administering the Challenge, evaluating the contents of the Submission, and as otherwise provided herein. Entrants are not under any obligation to provide personal information; however, the administration of the Challenge with regard to an Entrant who does not provide certain information may not be possible. All entry information and materials, including any copy of the Submission submitted to Roche, become the property of Roche and will not be acknowledged or returned. Proof of uploading a Submission is not considered proof of delivery to or receipt of such Submission by Roche. Furthermore, Roche and/or the Collaborators (as defined below) shall have no liability for any Submission that is lost, intercepted, or not received by Roche. Roche and/or the Collaborators (as defined below) assumes no liability or responsibility for any error, omission, interruption, deletion, theft, or destruction or unauthorized access to, or alteration of, Submissions. Notwithstanding the foregoing, SNC shall have no liability for the Challenge, the Submission Website and/or the prizes (as defined below). Affiliates of Roche, Medical Center, SNC, as well as other third parties including for example advisors and Advisory Committee members, in or outside of Israel (Medical Center, SNC and all other foregoing bodies, entities and persons, collectively: “Collaborators”) will have access to the Submission as well as any other material, document, data, information (including personal information) and/or activity in relation to the Challenge (and for clarity Roche and Collaborators may exchange any Submission and other documents, data and information regarding Entrants). Roche shall not pay any costs and/or expenses incurred in the preparation of the Submission.

REPRESENTATIONS AND WARRANTIES/INDEMNIFICATION:

By participating in the Challenge, each Entrant represents, warrants, and covenants as follows:

(a) Entrant is the sole author and creator of the Submission and all other content and information submitted by the Entrant; (b) the information supplied in the Submission is true and correct to the best of Entrant’s knowledge, information and belief; (c) Entrant meets the eligibility requirements set forth in these Official Rules; (d) Entrant’s signatory is authorized to represent Entrant and to bind Entrant to these Official Rules; (e) neither the Entrant nor any content or information contained in the Submission is the subject of any actual or threatened litigation, claim, investigation, audit or other civil or criminal proceeding by any governmental entity or private third party; and (f) neither the Entrant nor any of its direct or indirect owners has a direct or indirect financial relationship or compensation arrangement with a current employee, officer or director of Roche or any of its affiliates and/or Medical Center. In Addition, in the frame of the Submission each Entrant shall disclose (in order for Roche and Medical Center to examine at their sole and unfettered discretion a potential situation of a conflict of interest) any current or past relation and/or agreement that Entrant and/or its owners may have vis-à-vis Roche and/or any of its affiliates and/or Medical Center.   

If the Submission includes any third party works (such as third party content or open source code), Entrant must be able to provide, upon Roche’s request, all appropriate licenses and releases for such third party works. In the event Entrant cannot provide all required licenses and releases, Roche reserves the right, in Roche’s sole discretion, to disqualify the applicable Submission, or seek to secure the licenses and releases for Roche’s benefit and allow the applicable Submission to remain in the Challenge. Feedback provided in a Submission or in any other manner regarding products and/or technology and/or services of Roche and/or an affiliate thereof will not be treated as confidential or protected by intellectual property of any kind, and Roche is free to use such feedback on an unrestricted basis with no compensation to Entrant.

By participating in the Challenge, Entrant agrees to indemnify, defend, and hold harmless Roche and Collaborators from and against all third party claims, actions, or proceedings of any kind and from any and all damages, liabilities, costs and expenses relating to or arising from Entrant’s Submission or any breach or alleged breach of any of the representations, warranties and covenants of Entrant hereunder. Roche reserves the right to disqualify any Submission that Roche, in its sole discretion, deems to violate these Official Rules.

SUBMISSION LICENSE; CONFIDENTIALITY:

EACH ENTRANT RETAINS TITLE AND FULL OWNERSHIP IN AND TO THEIR SUBMISSION. ENTRANT EXPRESSLY RESERVES ALL INTELLECTUAL PROPERTY RIGHTS NOT EXPRESSLY GRANTED UNDER THIS AGREEMENT. By participating in the Challenge, each Entrant hereby irrevocably grants to Roche, Medical Center and SNC a limited, non-exclusive, royalty free, worldwide, license and right to use the Submission solely to the extent necessary to administer the Challenge, and to publicly perform and publicly display the Submission, including, without limitation, for advertising and promotional purposes relating to the Challenge. In the event that Roche shall decide to publicly display the Submission as above-mentioned, Entrants will be granted in such display an acknowledgment containing Entrant’s name and logo.

Entrant understands and agrees that it should only provide information in or with its Submission that it is willing to allow Roche to use and/or disclose (e.g. to Collaborators) and/or publicize without any expectation that Roche and/or SNC and/or any other third party will hold such information in confidence. Entrant acknowledges and agrees that Roche, SNC and other third parties on their behalf do not have any obligation to keep the Submission and/or any other information, data and documents provided by Entrant in relation to the Challenge confidential and no confidentiality obligation is established by Entrant’s Submission or by any additional disclosures of Entrant, including but not limited during the Finalist Showcase Event.

Entrant understands and agrees that it is solely responsible for obtaining appropriate legal protection for its intellectual property rights before disclosing its inventions, ideas, data, documents and/or material to Roche or any other entity on a non-confidential basis or it risks losing the ability to protect these according to applicable law.

PUBLICITY RELEASE:

By participating in the Challenge, each Entrant hereby irrevocably (a) grants to Roche and Medical Center and SNC the right to use such Entrant’s name, likeness, image, and biographical information in any and all media for any purpose, including, without limitation, advertising and promotional purposes relating to the Challenge, and (b) releases Roche and Collaborators from any liability with respect thereto.

Participation in the Challenge does not confer any right on the Entrant to use any name, trademark, service mark or other designation of Roche and/or any entity affiliated with Roche (including any contraction, abbreviation, or simulation of Roche name) and/or any other Collaborator in advertising, publicity or any promotional activities.

WINNER SELECTION/EVALUATION CRITERIA:

First Round

An advisory committee selected by Roche (“Advisory Committee”) will select up to six (6) finalists from all eligible Submissions. Evaluation criteria for the First and Second Rounds may include for example and without limitation: quality of founding team, interest area fit, runway, does the solution address a real need, maturity and timeline, novelty and effectiveness and general impression. In addition, the Advisory Committee will consider the feasibility of performing the suggested pilot in Medical Center.

Above evaluation criteria may vary according to the sole discretion of Roche.

Second Round

All finalists will be notified by the Finalist Notification Date and required to participate in a meeting with the Advisory Committee members, Roche, Medical Center and SNC during which the finalists will present their solutions and answer questions of the Advisory Committee members, and in the live finalist showcase/pitch event (via video conference / live, as will be determined by Roche) (“Showcase Event”). It is recorded that the Showcase Event as well as Winner Announcement ceremony may be recorded by audio/video by Roche, Medical Center, SNC and/or anyone on their behalf, and Entrants provide their approval (and have procured the approval of their staff and anyone else on their behalf participating in the Showcase Event) for the use by Roche, Medical Center, SNC and/or anyone on their behalf of such recording/s or any part thereof (including public use such as for example posting on a Roche website and/or Submission Website).

NOTICE TO FINALISTS AND WINNERS:

Attempts to notify potential finalists will be made using the contact information provided on the Entrant’s Submission. Roche is not responsible for e-mail or other communication problems of any kind. If, despite reasonable efforts, a potential finalist does not respond within three (3) days of the first notification attempt, such potential finalist will (unless approved otherwise by Roche) forfeit its rights and an alternate Finalist may be selected.

Prize winner will be notified during the Showcase Event. Roche is not responsible for e-mail or other communication problems of any kind. If, despite reasonable efforts, a potential winner does not respond within three (3) days of the first notification attempt such potential winner will (unless approved otherwise by Roche) forfeit its prize and an alternate winner may be selected by Roche.

If any potential finalist or prize winner is found to be ineligible, or if the potential finalist or prize winner is determined not to have complied with these Official Rules or declines the applicable prize for any reason prior to award, such potential finalist or prize winner will be disqualified and an alternate finalist or winner may be selected by Roche.

PRIZES AND CONDITIONS:

Following the Advisory Committee’s recommendation, Roche and Medical Center will, in their sole discretion (and without need to provide reasons), select one winner of the Challenge. Each Entrant unconditionally acknowledges and agrees to be bound by the final winner selection of Roche and Medical Center, which decision shall be final and binding in all respects and is not subject to any appeal.

Winner of the Challenge will be entitled to receive:

• a gross amount of NIS 50,000 (VAT inclusive) to be used by the winner solely to advance the development of the submitted solution and undertake Pilot (as defined below) activities (“Monetary Grant”). The Monetary Grant shall be subject to signing a separate agreement and shall be provided against a tax invoice. No additional requirements are imposed;
• financing for a pilot / proof of concept / study in a gross amount of up to NIS 200,000 (two hundred thousand New Israeli Shekels) (VAT and overhead inclusive) (“Pilot Budget”) to be performed at Medical Center in relation to the Submission solution of the winner Submission (“Pilot”). In relation thereof it is noted as follows:
  • The Pilot Budget shall cover the costs and expenses of the support of and/or performance by Medical Center of its activities under the Pilot and shall not cover any other costs (i.e. the Pilot Budget shall not be directed to cover winner expenses such as salaries, payment to third parties, activities outside of Medical Center etc.). For clarity – winner shall make its technology available to the Pilot at no cost. 
  • The final Pilot Budget (i.e. actual prize) payable by Roche and/or an affiliate thereof (and transferred to Medical Center) shall be subject to written approval of both Roche and Medical Center, it being noted that in any event the finance shall not exceed a gross amount of NIS 200,000 (VAT and overhead inclusive).
  • Taking into account inter alia that the Submission does not include a complete Pilot protocol and budget and that as recorded below further approvals are required in order to perform the Pilot (including an approval of Roche, an additional affiliate of Roche and an approval of independent review board, as well as other factors), there is always a possibility that the Pilot shall not be approved by all parties / shall not be performed. For clarity – winner shall have no claim or demand or assertion against Roche and/or Medical Center in any event where for any reason the Pilot shall not be performed for any reason. In that situation, eligibility of winner to collect the Monetary Grant shall be maintained.  
  • a right to receive support and services from the ARC Center for Digital Innovation (“ARC“) of the Medical Center, for a period of one year at no cost. This support includes, by way of example: the opportunity to participate in ARC events and gain exposure; consulting services from ARC’s professional team; and assistance with activities involving the Medical Center. All activities of the winner with ARC shall be without involvement, responsibility, or funding on the part of Roche.
  • 5 mentorship hours with a medical expert from the Breast Cancer Institute, Department of Oncology of Medical Center;
    if applicable – 5 mentorship hours with Medical Center supporting submission to Helsinki Committee;
  • 2 mentorship hours with Dr. Irit Yaniv, Co-founder and Chairperson of Almeda ventures.

The winner will be required to accept the terms and conditions recorded above and below to exercise the prize. In addition, the winner will be required to execute vis-à-vis Roche – a prize letter in a form provided by Roche according to its sole and unfettered discretion (“Roche Prize Letter“).

Additional Pilot related provisions:

• The Pilot and Pilot protocol require the approval of Roche, an additional affiliate of Roche, Medical Center and its independent review board. As a general rule, Roche shall not provide under the Pilot any Roche drugs (or other technology) and furthermore potential pilots which require the provision of treatment to patients (as opposed to observational studies which do not amend the regular patient treatment) shall not be approved. 
• The Pilot shall be performed under a separate agreement between Roche and Medical Center (to which winner shall not be a party) while winner shall be required to execute vis-à-vis Medical Center a separate agreement underlying the winner’s rights, responsibilities and undertakings in relation to the Pilot in a form approved by Medical Center and Roche according to their sole and unfettered discretion (“Medical Center Pilot Agreement” and together with Roche Prize Letter: “Prize Documents”). It is recorded that while Roche is not a party to the Medical Center Pilot Agreement and shall bear no liability in connection thereto – Medical Center /winner shall provide Roche (at no additional cost to Roche) with the results of the Pilot (“Pilot Results”) including the final Pilot report as well as all anonymized raw data obtained in the course of the Pilot (“Data”), within 60 days from Pilot completion.
• The Pilot shall be performed in compliance with all applicable Roche procedures and guidelines as shall be presented by Roche.
• Roche will not be involved in the development of the technology subject of the Pilot.
• Under no circumstances shall Roche commit to using the technology subject of the Pilot in any Roche sponsored study and Roche shall not provide specifications for said technology.
• For the sake of good order it is noted that Pilot Results and all related intellectual property rights shall be the property of winner. However Roche and its affiliates and its collaboration partners shall be entitled to use the Results and Data for any purpose whatsoever, including publication, without the obligation to pay any amount to Medical Center and/or winner. Also – winner shall not be entitled to file patent applications for invention or discovery arising directly from the Pilot, if related solely or in combination to a Roche or Roche affiliate product(s). Such inventions and/or discoveries shall belong to Roche and Roche shall be solely entitled to patent such inventions and/or discoveries and to register and file intellectual property (e.g. patent application) claiming the foregoing alone or with collaboration with other partners. Further rights shall be recorded in the agreement/s under which the Pilot shall be performed.

SNC shall not bear any responsibility for any financial or non-financial commitments of the Monetary Grant and/or the Pilot and/or the Pilot Budget.

If a winner fails or refuses to sign and return the Prize Documents within thirty (30) days of Roche’s/ Medical Center’s (as applicable) request, the potential winner may be disqualified and an alternate winner may be selected. No cash alternative or substitution or transfer of prizes will be allowed. For clarity – winner shall not be entitled to any consideration or other compensation under the Medical Center Pilot Agreement and/or the Roche- Medical Center agreement for the performance of the Pilot (in relation to winner’s technology subject of the Pilot or otherwise). Winner is responsible for reporting and paying any income taxes or other taxes that may apply to accepting a prize; and neither Roche nor Medical Center are responsible for and will not pay any such taxes.

DATES/DEADLINES:

Because of the unique nature and scope of the Challenge, Roche, SNC and Medical Center reserve the right, in addition to those other rights reserved herein, to modify any dates or deadlines set forth in these Official Rules or otherwise governing the Challenge for any reason. Entrants will be notified of such changes according to the contact information provided in their Submissions.

GENERAL LIABILITY RELEASE/FORCE MAJEURE:

Each Entrant agrees that neither Roche nor Collaborators nor anyone on their behalf (a) shall be responsible or liable for any losses, damages, or injuries of any kind (including death) resulting from participation in the Challenge or any Challenge-related activity, or from Entrants’ acceptance, receipt, possession, use, or misuse of any prize, and (b) makes any warranty, representation, or guarantee, express or implied, in fact or in law, with respect to any prize, including, without limitation, regarding such prize’s merchantability or fitness for a particular purpose. Entrants will indemnify, defend, and hold harmless Roche and Collaborators and anyone on their behalf from and against all third party claims, actions, or proceedings of any kind and from any and all damages, liabilities, costs, and expenses relating to or arising from Entrant’s participation in the Challenge. Roche and Collaborators assume no responsibility for any damage to an Entrant’s computer system which is occasioned by accessing the Submission Website or other Challenge-related websites or participating in the Challenge, or for any computer system, phone line, hardware, software, or program malfunctions, or other errors, failures, delayed computer transmissions, or network connections that are human or technical in nature. Without limiting the generality of the foregoing, Roche and Collaborators are not responsible for incomplete, illegible, misdirected, misprinted, late, lost, damaged, or stolen entries or prize notifications; or for lost, interrupted, inaccessible, or unavailable networks, servers, satellites, Internet Service Providers, websites, or other connections; or for miscommunications; or for any technical malfunctions, failures, difficulties, or other errors of any kind or nature; or for the incorrect or inaccurate capture of information, or the failure to capture any information. Roche reserves the right in its sole discretion to disqualify any Entrant who is found to be tampering with the entry process or the operation of the Challenge or Submission Website or other Challenge-related websites, to be acting in violation of these Official Rules, or to be acting in an unsportsmanlike or disruptive manner, or with the intent to disrupt or undermine the legitimate operation of the Challenge, or to annoy, abuse, threaten, or harass any other person, and Roche reserves the right to seek damages and other remedies from any such Entrant to the fullest extent permitted by law. In the event an insufficient number of eligible entries are received or Roche is prevented from awarding the prize or continuing with the Challenge as contemplated herein by any event beyond its control, including, without limitation, fire, flood, natural or man-made epidemic, earthquake, explosion, labor dispute or strike, act of God or public enemy, satellite or equipment failure, riot or civil disturbance, terrorist threat or activity, war (declared or undeclared) or any law, order, or regulation, public health crisis, order of any court or jurisdiction, or other cause not reasonably within Roche’s control (“Force Majeure“), Roche shall have the right to modify, suspend, or terminate the Challenge. If the Challenge is terminated for Force Majeure before expiration of the Challenge Period, Roche and Medical Center may decide to select a winner from all eligible, non-suspect entries received as of the date of the event giving rise to the termination. These Official Rules cannot be modified or amended in any way except in a written document issued by a duly authorized representative of Roche. The invalidity or unenforceability of any provision of these Official Rules shall not affect the validity or enforceability of any other provision. In the event that any provision is determined to be invalid or otherwise unenforceable or illegal, these Official Rules shall otherwise remain in effect and shall be construed in accordance with their terms as if the invalid or illegal provision were not contained herein.

GOVERNING LAW/JURISDICTION:

All issues and questions concerning the construction, validity, interpretation, and enforceability of these Official Rules and the rights and obligations of Entrants or Roche in connection with the Challenge and any aspect of the Challenge shall be governed by and construed in accordance with the laws of Israel and any and all disputes relating to a Submission and/or subsequent interaction with Roche and/or these Official Rules and/or the Challenge shall be exclusively referred to the courts located in Tel Aviv, Israel.